Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EHA 2023 | Mechanism of action of bitopertin to treat patients with EPP

William Savage, MD, PhD, Disc Medicine, Watertown, MA, comments on the mechanism of action of bitopertin, an oral and selective inhibitor of glycine type 1 (GlyT1), which is currently being developed for the treatment of erythropoietic protoporphyria (EPP). This interview took place at the 28th Congress of the European Hematology Association (EHA) 2023 in Frankfurt, Germany.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.


Employee and stakeholder of Disc Medicine